Trial Profile
Real-world comparative effectiveness of Vedolizumab and Anti-Tumour Necrosis Factor Agents
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2019
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018
- 04 Dec 2017 New trial record
- 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week